OpenAI Launches GPT-Rosalind, an AI Model for Drug Discovery Research

Gate News message, April 17 — OpenAI unveiled an early-stage version of GPT-Rosalind, an artificial intelligence model designed to accelerate drug discovery and life sciences research, on April 16. The model will initially be available as a research preview to enterprise customers, with early users including pharmaceutical company Amgen, vaccine producer Moderna, and the Allen Institute for Brain Science.

GPT-Rosalind is designed to help researchers extract insights from large datasets and translate scientific findings into patient-focused healthcare applications. Named after biophysicist Rosalind Franklin, the model integrates large language models with specialized biochemical knowledge to support complex scientific reasoning across evidence synthesis, hypothesis generation, and multi-step experimental planning.

OpenAI CEO Sam Altman indicated the company plans to shift its business model beyond subscription fees, moving toward sharing drug development risks with pharmaceutical companies and collecting technology royalties after drug approvals. Following the announcement, stock prices of drug discovery-focused companies declined: IQVIA fell 3.45%, Charles River Laboratories dropped 2%, Recursion Pharmaceuticals fell 4%, and Schrodinger declined nearly 3%.